Impact of 2016 UNOS pediatric heart allocation policy changes on VAD utilization, waitlist, and post‐transplant survival outcomes in children with CHD versus Non‐CHD.

Aims: We analyzed the impact of the revised pediatric heart allocation policy on types of ventricular assist device (VAD) utilization, and waitlist (WL) and post‐heart transplant (HT) survival outcomes in congenital heart disease (CHD) versus non‐CHD patients before (Era‐1) and after (Era‐2) pediatric heart allocation policy implementation. Methods: We retrospectively reviewed the UNOS database from December 16, 2011, through March 31, 2021, for patients < 18 years old and listed for primary HT. We compared the differences observed between Era‐1 and Era‐2. Results: 5551 patients were listed for HT, of whom 2447(44%) were in Era‐1 and 3104(56%) were in Era‐2. CHD patients were listed as status 1A unchanged, but the number of patients listed as status 1B decreased in Era‐2, whereas the number of non‐CHD patients listed as status 1A decreased, but status 1B increased. In Era‐2 compared to Era‐1, both temporary (1% to 4%, p <.001) and durable VAD (13.6% to 17.8%, p <.001) utilization increased, and the transplantation rate per 100‐patient years increased in both groups. The median WL period for CHD patients increased marginally from 70 to 71 days (p =.06), whereas for non‐CHD patients it decreased from 61 to 54 days (p <.001). Adjusted 90‐day WL survival increased from 84% to 88%, p =.016 in CHD, but there was no significant change in non‐CHD patients (p =.57). There was no significant difference in 1‐year post‐HT survival in CHD and non‐CHD patients between Era‐1 and Era‐2. Conclusions: In summary, after the revised heart allocation policy implementation, temporary and durable VAD support increased, HT rate increased, waitlist duration marginally increased in the CHD cohort and decreased in the non‐CHD cohort, and 90‐day WL survival probability improved in children with CHD without significant change in 1‐year post‐HT outcomes. Future studies are needed to identify changes to the policy that may further improve the listing criteria to improve WL duration and post‐HT survival. [ABSTRACT FROM AUTHOR]